3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Venous Thromboembolism
17
Neoplasms
11
Venous Thrombosis
7
Pulmonary Embolism
7
Thrombosis
5
Multiple Myeloma
4
Upper Extremity Deep Vein Thrombosis
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Intracranial Thrombosis
2
Hematologic Neoplasms
2
Carcinoma, Hepatocellular
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thromboprophylaxis
1
Thromboembolism
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Mesenteric Ischemia
1
Lymphoma
1
Leukemia
1
Head and Neck Neoplasms
1
Glioma
1
Interventions
Temozolomide
109
Magnetic Resonance Spectroscopy
52
Bevacizumab
52
Radiotherapy
44
Irinotecan
27
Blood Specimen Collection
19
Surgical Procedures, Operative
16
Radiation
15
Aminolevulinic Acid
15
Carboplatin
13
fluorodopa F 18
12
Nivolumab
12
Radiotherapy, Intensity-Modulated
11
Carmustine
11
Radiosurgery
10
Magnetic Resonance Imaging
10
pembrolizumab
9
Topotecan
9
Specimen Handling
9
Everolimus
9
Erlotinib Hydrochloride
9
Biopsy
9
poly ICLC
8
Surveys and Questionnaires
8
Standard of Care
8
Etoposide
8
Drug Therapy
8
Lomustine
7
Filgrastim
7
Cyclophosphamide
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Glioma
×
apixaban
×
Clear all
NCT05683808
2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2
Recruiting
40 enrolled